724. Clinical utility of novel antipsychotics in schizophrenia
Abstract Background Antipsychotic development in schizophrenia has been constrained by reliance on dopamine D2 receptor blockade, yielding modest incremental efficacy alongside persistent adverse-effect burden. Recent agents and late-stage pipelines aim to expand mechanisms of action, most notably via central muscarini...